Scholarlink

Purpose <p>Tumor/node/metastasis staging and prognostic index (PI) are used to predict prognosis and guide treatment for anaplastic thyroid carcinoma (ATC). With the advent of treatments, such as BRAF/MEK inhibitors and immune checkpoint inhibitors, dynamic markers to assess disease status and treatment efficacy are needed. This study examined the utility of PI as a dynamic marker for ATC treatment.</p> Methods <p>This retrospective study investigated 20 patients with ATC who were treated aggressively from January 2011 to December 2022. Patients were categorized into low-, high-, low-, and high-high groups according to the PI before and after treatment. Survival was then compared between the groups.</p> Results <p>The median overall survival was not reached for the Low–Low, 363&#xa0;days for the High–Low, 158.5&#xa0;days for the Low–High, and 90.5&#xa0;days for the High–High groups (<i>p</i> &lt; 0.01). Among the 13 patients with an initially high PI, 6 patients achieved a low PI during treatment, but three showed subsequent increases. Categorizing PI further into decreased, temporarily decreased, and non-decreased groups, median overall survival was 363&#xa0;days, 158.5&#xa0;days, and 87&#xa0;days, respectively (<i>p</i> &lt; 0.01).</p> Conclusion <p>PI is a critical prognostic indicator that facilitates treatment decision-making for ATC. PI may also have potential as a dynamic marker for assessing the disease status and treatment efficacy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Dynamics of the prognostic index during the course of treatment for anaplastic thyroid carcinoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年1月6日

查看全文
  • Masaomi Sen,
  • Ryo Ito,
  • Takeshi Abe,
  • Hiroko Kazusaka,
  • Mami Matsui,
  • Marie Saitou,
  • Ryuta Nagaoka,
  • Tomoo Jikuzono,
  • Iwao Sugitani

摘要

Purpose

Tumor/node/metastasis staging and prognostic index (PI) are used to predict prognosis and guide treatment for anaplastic thyroid carcinoma (ATC). With the advent of treatments, such as BRAF/MEK inhibitors and immune checkpoint inhibitors, dynamic markers to assess disease status and treatment efficacy are needed. This study examined the utility of PI as a dynamic marker for ATC treatment.

Methods

This retrospective study investigated 20 patients with ATC who were treated aggressively from January 2011 to December 2022. Patients were categorized into low-, high-, low-, and high-high groups according to the PI before and after treatment. Survival was then compared between the groups.

Results

The median overall survival was not reached for the Low–Low, 363 days for the High–Low, 158.5 days for the Low–High, and 90.5 days for the High–High groups (p < 0.01). Among the 13 patients with an initially high PI, 6 patients achieved a low PI during treatment, but three showed subsequent increases. Categorizing PI further into decreased, temporarily decreased, and non-decreased groups, median overall survival was 363 days, 158.5 days, and 87 days, respectively (p < 0.01).

Conclusion

PI is a critical prognostic indicator that facilitates treatment decision-making for ATC. PI may also have potential as a dynamic marker for assessing the disease status and treatment efficacy.